Table 1 Patient characteristics.
From: Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups
Feature | Freq N (%) or mean (range) |
|---|---|
Patient age (n = 255) | 66.0 (33–92) |
BMI (n = 249) | 30.6 (16–60) |
Menopausal status (n = 255) | |
Pre menopausal | 12 (4.7%) |
Post menopausal | 231 (90.6%) |
Peri menopausal | 12 (4.7%) |
Endometrioid | 212 (83.1%) |
Serous | 12 (4.7%) |
Mucinous | 3 (1.2%) |
Histological subtype (n = 255) | |
Clear cell carcinoma | 7 (2.7%) |
Villoglandular | 12 (4.7%) |
Other | 9 (3.5%) |
pT1a | 123 (48.2%) |
pT1b | 70 (27.5%) |
pT2 | 33 (12.9%) |
T-category | |
pT3a | 14 (5.5%) |
pT3b | 13 (5.1%) |
pT4 | 2 (0.8%) |
cN0 | 47 (18.4%) |
cN1 | 1 (0.4%) |
N-category | |
pN0 | 163 (63.9%) |
pN1 | 44 (17.3%) |
None | 48 (18.8%) |
Pathological lymph node examination | |
Sentinel only | 14 (5.5%) |
Dissection | 193 (75.7%) |
Sentinel only | 3.1 (1–6) |
Number of lymph nodes | |
Dissection | 32.2 (2–85) |
G1 | 92 (36.1%) |
Tumor grade | |
G2 | 107 (42.0%) |
G3 | 56 (22.0%) |
L0 | 197 (77.3%) |
Lymphatic invasion | |
L1 | 58 (22.7%) |
V0 | 201 (78.8%) |
Venous invasion | |
V1 | 54 (21.2%) |
Present | 48 (18.8%) |
MELF pattern | |
Not present | 207 (81.2%) |
POLEmut | 10 (3.9%) |
MMRdef | 81 (31.8%) |
TCGA subgroups | |
NSMP | 132 (51.8%) |
P53abn | 32 (12.5%) |
